SCM
ATNM icon

Sterling Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Sterling Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31
Closed -$50 – 3276
2025
Q1 		$50 Hold
31
– – ﹤0.01% 3180
2024
Q4 		$39 Hold
31
– – ﹤0.01% 3220
2024
Q3 		$58 Buy
+31
New +$122 ﹤0.01% 3231

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Sterling Capital Management's ATNM Position: Q2 2025 in Review

Sterling Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q2 2025, closing a stake of 31 shares — an estimated $50 sold.

Sterling Capital Management first reported a position in ATNM in Q3 2024 and held it in 3 quarters. The position peaked at $58 in Q3 2024. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.

  • Sterling Capital Management reported no remaining Actinium Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 31 Actinium Pharmaceuticals shares in Q2 2025, an estimated $50.
  • Sterling Capital Management first reported a position in Actinium Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Actinium Pharmaceuticals position peaked at $58 in Q3 2024.
  • 63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.